Kantarjian et al53 assessed the efficacy and protection of dasatinib, as when compared with imatinib, for the main-line treatment of CML-CP. Five hundred and nineteen individuals with newly diagnosed CML-CP were randomly assigned to acquire dasatinib in a dose of one hundred mg after every day (259 clients) or imatinib https://waltg186txa8.worldblogged.com/profile